Business

Cipla has announced that it will launch the Synchrobreathe breath-actuated inhaler, which the company says requires low inspiratory flow to actuate, by the end of 2015. Company executives discussed the new inhaler at the 2015 South Africa Thoracic Society Conference. Cipla Global Head of Respiratory Frank Pieters commented, “Simple and intuitive, Synchrobreathe is … [Read more...] about Cipla announces the upcoming launch of the Synchrobreathe inhaler

Turing Pharmaceuticals, which is developing intranasal oxytocin for several indications has announced the completion of $90 million Series A financing round led by its Founder and CEO, Martin Shkreli. According to Turing, "the financing included participation from multiple preeminent institutional equity investors," but none were named. Retrophin divested intranasal … [Read more...] about Turing Pharmaceuticals announces that it has raised $90 million

Lupin Limited has officially opened its new Center of Excellence for Inhalation Research in Coral Springs, Florida with a ceremony officials from the city and the state of Florida. The new center will employ 45 OINDP specialists. Lupin CEO Vinita Gupta commented, "We are delighted to be making our mark in South Florida. With the talent and resources this state … [Read more...] about Lupin celebrates grand opening of Center of Excellence for Inhalation Research

According to a spokesperson for GlaxoSmithKline, GSK is aiming to hire a total of 100 employees in 2015 and another 30-40 employees in 2016 for a new DPI assembly line at its Zebulon, NC manufacturing facility. The Zebulon plant, which manufactures and packages 65 million Advair, Breo, Ventolin, Serevent, and Flovent inhalers per year, currently has 850 … [Read more...] about GSK hiring for new DPI production line at North Carolina facility

New Zealand-based Smartinhaler maker Adherium (formerly Nexus6) is looking to raise a minimum of A$20 million (~ US$14.7 million) up to a maximum of A$35 million (~US25.7 million) through an initial public offering on the Australian Securities Exchange (ASX). Between 40 and 70 million shares will be offered at 50 cents/share. Proceeds are intended for … [Read more...] about Adherium looks to raise at least A$20 million through IPO

Discovery Laboratories has announced the completion of a public offering that raised over $40 million as well as the receipt of a $1 million supplement from a Phase 2 Small Business Innovation Research (SBIR) grant that was initially announced in October 2014. The grant supports development of Discovery Labs' aerosolized KL4 surfactant for the treatment of … [Read more...] about Discovery Labs gets additional funding for development of aerosolized KL4 surfactant

Moerae Matrix has initiated a lipopolysaccharide (LPS) challenge study of its MMI-0100 inhaled MAPKAP kinase 2 (MK2) inhibitor to evaluate its safety and tolerability in smokers, the company said. Moerae is developing MMI-0100 as a DPI for the treatment of idiopathic pulmonary fibrosis and other pulmonary diseases and has already conducted one Phase 1 study. In … [Read more...] about Moerae Matrix announces initiation of second Phase 1 study of inhaled MK2 inhibitor

Inhaled vaccine developer Ansun BioPharma, formerly NexBio, has announced that the US Attorney's office investigation of misconduct by the company's former CEO and CFO has been dismissed. As part of that investigation, the US Federal Bureau of Investigation (FBI) raided the California headquarters of NexBio in August 2011. According to a January 2015 announcement … [Read more...] about Investigation into Ansun BioPharma dismissed